Xandra Breakefield, PhD, on Trying New Approaches to AAV Therapy for Glioblastoma

Commentary
Video

The investigator of neurology at Mass General Research Institute discussed research from her grad student, Lisa Nieland, presented at the ASGCT 2024 meeting.

"The thing I liked the best [about the research] was that it was really Lisa [Nieland’s] idea as a graduate student, she had me as a mentor who was a little [iffy about it] but she persisted and she was successful. I think this is about as exciting as it could be for a graduate student and teaches us all that we may have our preconceived notions about what is going to work and what isn't, but you don't know in science until you try.”

Glioma, and specifically glioblastoma, is an aggressive brain tumor with historically very poor outcomes, with a 1-year survival rate of 40% and a 2-year survival rate of 17%. The disease is a difficult one to treat, within the inherently challenging environment of the brain along with the blood brain barrier and potential neurotoxicity with targeted therapies.1

Research out of the lab of Xandra Breakefield, PhD, investigator of neurology, Mass General Research Institute, and professor of neurology, Harvard Medical School, by Lisa Nieland, PhD candidate, was presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, held May 7 to 10, 2024, in Baltimore, Maryland, that investigated adeno-associated virus (AAV) delivery of Staphylococcus aureus Cas9 (saCas9) guided by a single-guide RNA to target microRNA-21 (miR-21) coding sequences in the genome in vivo. miR-21 is highly expressed in glioma cells responsible for tumor progression. The approach yielded reduced tumor growth and improved survival in mouse models.2

REFERENCES
1. Glioblastoma Multiforme. Webpage. 2024. American Association of Neurological Surgeons. https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme 
2. Nieland L, Vrijmoet AB, Jetten IW, et al. All-in-One Adeno-Associated Virus Delivery for Therapeutic miR-21 Editing by saCas9 In Vivo. Presented at: ASGCT 27th Annual Meeting, May 7-10; Baltimore, Maryland. Abstract #113
Related Videos
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
Marcus Conant, MD, on More Research Needed With HIV Therapies
© 2024 MJH Life Sciences

All rights reserved.